Search
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigational[A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDiflunisal
go.drugbank.com/drugs/DB00861ApprovedDiflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though it...
Products: Nu-diflunisal Tab 500mg, Nu-diflunisal Tab 250mgPaeonia lactiflora root
go.drugbank.com/drugs/DB16595InvestigationalMixtures: HAN SHIN GAMKONAL Extract Granules, HAN SHIN GAMKONAL Extract GranulesRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalan action potential. … [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973]
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIn fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Mixtures: Face It Hd Perfect Bb Spf30 Pa 02, Face It Hd Perfect Bb Spf30 Pa 01Products: Pan Aromas BabyManidipine
go.drugbank.com/drugs/DB09238ApprovedInvestigationalWithdrawnManidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsPimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide
Synonyms: Pg-545 free acidTasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAdverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. … High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.